Plain-English translation of NCT06994676 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 study testing a new medication called for people with certain types of blood cancer—including acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, and chronic myeloid leukemia—that have stopped responding to standard treatments. The medication is given as injections under the skin in 28-day cycles. Researchers want to find the right dose and learn how safe and effective this treatment is.
People with these types of blood cancer often run out of treatment options, especially if their disease comes back or doesn't respond to initial therapy. This trial exists to see whether this medication could offer a new hope for patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
If accepted, you would receive injections of the medication under your skin on a set schedule within 28-day treatment cycles. Your first cycle includes a 7-day 'priming' phase followed by 28 days of the target treatment phase; later cycles are 28 days each. You would continue treatment as long as the cancer is not growing and you are tolerating the injections well. You would have regular doctor visits and tests to monitor your response and watch for any side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States